Comparative Pharmacology
Head-to-head clinical analysis: PALBOCICLIB versus VERZENIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALBOCICLIB versus VERZENIO.
PALBOCICLIB vs VERZENIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase (CDK) 4 and 6 inhibitor; blocks phosphorylation of retinoblastoma protein, preventing cell cycle progression from G1 to S phase.
Selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which prevents phosphorylation of retinoblastoma protein, blocking cell cycle progression from G1 to S phase and reducing cancer cell proliferation.
125 mg orally once daily for 21 days, followed by 7 days off treatment; taken with food in combination with an aromatase inhibitor or fulvestrant.
150 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life of 24-29 hours, supporting once-daily dosing; steady-state reached within 8 days.
Clinical Note
moderatePalbociclib + Deslanoside
"Palbociclib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePalbociclib + Acetyldigitoxin
"Palbociclib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderatePalbociclib + Ouabain
"Palbociclib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderatePalbociclib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Palbociclib."
Terminal elimination half-life is approximately 18 hours; supports once-daily dosing. Clinically, steady-state is achieved within 5 days.
Primarily hepatic metabolism (CYP3A4) with 74% fecal excretion (17% as unchanged drug) and 18% renal excretion (1.5% unchanged).
Primarily fecal (≥91%) as unchanged parent drug and metabolites; renal excretion accounts for <1%.
Category D/X
Category C
CDK4/6 Inhibitor
Cyclin-Dependent Kinase 4/6 Inhibitor